David H. Harpole, Jr, MD, on Perioperative Durvalumab Plus Chemotherapy in Resectable NSCLC

October 02, 2023 By The ASCO Post Staff

David H. Harpole, Jr, MD, of Duke University Medical Center, discusses further exploratory analyses of patients with EGFR-mutated resectable non–small cell lung cancer (NSCLC) enrolled in the phase III AEGEAN study. In this trial, perioperative durvalumab plus neoadjuvant chemotherapy, vs neoadjuvant chemotherapy alone, significantly improved event-free survival and pathologic complete response (Abstract OA12.06).

Related Content